Research programme: Eg5 kinesin inhibitors - SuperGenAlternative Names: Eg5 kinesin inhibitor - SuperGen
Latest Information Update: 20 Apr 2011
At a glance
- Originator SuperGen
- Mechanism of Action KIF11 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Leukaemia; Solid tumours
Most Recent Events
- 20 Apr 2011 No development reported for Solid tumours in USA (unspecified route)
- 20 Apr 2011 No development reported for Leukaemia in USA (unspecified route)